A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
Condition: Shigellosis Interventions: Biological: Shigella 4V; Biological: MenACWY; Biological: Rabies; Biological: Diphtheria, Tetanus and Pertussis (DTaP); Biological: Placebo Sponsors: LimmaTech Biologics AG; Kenya Medical Research Institute; KEMRI-Wellcome Trust Collaborative Research Program Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diphtheria | Dysentery | Gastroenteritis | Kenya Health | Men | Rabies | Research | Study | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine